Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same author

Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.

European journal of nuclear medicine and molecular imaging·2026
Same author

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease.

Nature aging·2026
Same author

Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Jonathan Graff-Radford1, Jeremy A Syrjanen2, Prashanthi Vemuri3

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Plasma %p-tau217 levels predict tau-PET positivity, similar to amyloid-PET scans. This finding aids in predicting Alzheimer's disease progression using blood biomarkers.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Accurate prediction of tau-PET positivity is crucial for understanding Alzheimer's disease progression.
  • Existing methods like amyloid-PET have limitations in accessibility and cost.
  • Novel plasma biomarkers are needed for early and efficient disease detection.

Purpose of the Study:

  • To evaluate the predictive value of plasma %p-tau217, Aβ42/40 ratio, and the amyloid probability score (APS2) for incident tau-PET positivity.
  • To compare the predictive performance of plasma biomarkers against amyloid-PET centiloids.
  • To validate these predictors in independent cohorts.

Main Methods:

  • Utilized data from the Mayo Clinic Study of Aging (MCSA) and BioFINDER-2 cohorts.
  • Measured plasma markers using mass spectrometry (IP-MS; C2N) and performed amyloid-PET scans.
  • Employed Cox proportional hazard models to assess the association between baseline predictors and incident tau-PET positivity, adjusting for covariates.

Main Results:

  • Higher baseline plasma %p-tau217, amyloid-PET centiloid, and APS2 were significantly associated with an increased risk of progressing to tau-PET positivity in both cohorts.
  • Plasma Aβ42/40 ratio showed no significant association with incident tau positivity in the MCSA cohort but was inversely associated in BioFINDER-2.
  • The predictive performance of plasma %p-tau217 was comparable to amyloid-PET centiloids.

Conclusions:

  • Plasma %p-tau217 is a valuable predictor of tau-PET conversion, offering similar predictive information as amyloid-PET.
  • These findings support the potential of plasma %p-tau217 as a non-invasive biomarker for predicting Alzheimer's disease progression.
  • The study highlights the utility of plasma biomarkers in large-scale screening and clinical trials.